In addition, a phase III randomized clinical trial conducted by Baselga et al.[41] showed that everolimus combined with exemestane improved progression-free survival (PFS) in patients with hormone receptor-positive advanced breast carcinoma that was previously treated, compared with the exemestane plus placebo arm. This evidence concerns the gene NR4A1 and breast carcinoma.